Jeito Capital co-leads EUR 65 million (USD 71 M) financing in Corteria Pharmaceuticals, a French biopharmaceutical company developing novel treatments for cardiovascular diseases
September 07, 2023 03:00 ET
|
Jeito Capital
Jeito Capital co-leads EUR 65 million (USD 711M) financing in Corteria Pharmaceuticals, a French biopharmaceutical company developing novel treatments for cardiovascular diseases Jeito Capital...
Jeito Capital co-dirige un financement de 104 millions d’euros pour Noema Pharma, une biopharma pour Noema Pharma, une biopharma ciblant les maladies graves du système nerveux central
March 07, 2023 04:00 ET
|
Jeito Capital
Jeito Capital co-dirige un financement de 104 millions d’euros pour Noema Pharma, une biopharma ciblant les maladies graves du système...
Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders
March 07, 2023 04:00 ET
|
Jeito Capital
Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central...
Jeito Capital renforce son soutien à Pulmocide en participant à un nouveau financement de 52 millions de dollars
December 06, 2022 07:00 ET
|
Jeito Capital
Jeito Capital renforce son soutien à Pulmocide en participant à un nouveau financement de 52 millions de dollars Ce nouveau tour de table permettra d’accélérer le développement clinique et...
Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer
November 22, 2022 05:00 ET
|
Jeito Capital
Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients...
Jeito Capital investit dans CatalYm Jeito Capital investit dans CatalYm société biopharmaceutique allemande spécialisée en immuno-oncologie
November 22, 2022 05:00 ET
|
Jeito Capital
Jeito Capital investit dans CatalYm société biopharmaceutique allemande spécialisée en immuno-oncologie Jeito Capital co-dirige un financement de série C de 50 millions d'euros avec Brandon...
Jeito Capital réalise son 1er investissement aux Etats-Unis avec HI-Bio, biopharma spécialisée dans la médecine de précision des maladies auto-immunes
November 01, 2022 09:05 ET
|
Jeito Capital
Jeito Capital réalise son 1er investissement aux Etats-Unis avec HI-Bio, biopharma spécialisée dans la médecine de précision des maladies...
Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases
November 01, 2022 06:02 ET
|
Jeito Capital
Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with...
Jeito Capital co-leads EUR 80 million Series B financing in European oncology company, Precirix
March 16, 2022 03:00 ET
|
Jeito Capital
Jeito Capital co-leads EUR 80 million Series B financing in European oncology company, Precirix Jeito Capital chooses Precirix, a clinical-stage biotechnology company developing precision...
JEITO CAPITAL BECOMES A KEY PLAYER IN THE FINANCING OF LIFE SCIENCES IN EUROPE WITH THE CLOSING OF JEITO I AT €534 MILLION ($630 MILLION)
September 20, 2021 01:00 ET
|
Jeito Capital
JEITO CAPITAL BECOMES A KEY PLAYER IN THE FINANCING OF LIFE SCIENCES IN EUROPE WITH THE CLOSING OF JEITO I AT €534 MILLION ($630 MILLION)Jeito I exceeds target and becomes the largest European fund...